1294 Stock Overview
Manufactures and sells health supplement products in Taiwan. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 1/6 |
Past Performance | 5/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Hantech Bio-Technology Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | NT$91.90 |
52 Week High | NT$231.54 |
52 Week Low | NT$79.40 |
Beta | -0.27 |
1 Month Change | -1.39% |
3 Month Change | -2.03% |
1 Year Change | -0.025% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 226.34% |
Recent News & Updates
Recent updates
Shareholder Returns
1294 | TW Personal Products | TW Market | |
---|---|---|---|
7D | 0% | 0% | 0% |
1Y | -0.03% | -22.3% | 28.0% |
Return vs Industry: 1294 exceeded the TW Personal Products industry which returned -22.2% over the past year.
Return vs Market: 1294 underperformed the TW Market which returned 28.6% over the past year.
Price Volatility
1294 volatility | |
---|---|
1294 Average Weekly Movement | 4.7% |
Personal Products Industry Average Movement | 4.3% |
Market Average Movement | 4.4% |
10% most volatile stocks in TW Market | 7.8% |
10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 1294 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 1294's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | 152 | n/a | www.htbios.com |
Hantech Bio-Technology Co., Ltd. manufactures and sells health supplement products in Taiwan. It provides dietary supplements in gel, liquid, and powder forms under OEM or ODM partnerships. The company offers its dietary supplements in various packages, such as rectangle, curve, Z, round, wine bottle, and standing pouches.
Hantech Bio-Technology Co., Ltd. Fundamentals Summary
1294 fundamental statistics | |
---|---|
Market cap | NT$2.54b |
Earnings (TTM) | NT$177.00m |
Revenue (TTM) | NT$795.78m |
14.3x
P/E Ratio3.2x
P/S RatioIs 1294 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
1294 income statement (TTM) | |
---|---|
Revenue | NT$795.78m |
Cost of Revenue | NT$459.76m |
Gross Profit | NT$336.02m |
Other Expenses | NT$159.02m |
Earnings | NT$177.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 6.41 |
Gross Margin | 42.22% |
Net Profit Margin | 22.24% |
Debt/Equity Ratio | 30.6% |
How did 1294 perform over the long term?
See historical performance and comparisonDividends
0.8%
Current Dividend Yield11%
Payout RatioCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/30 05:44 |
End of Day Share Price | 2025/01/22 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hantech Bio-Technology Co., Ltd. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Hsiu Chi Lin | Masterlink Securities Corp. |